MDT-AP-2055
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 3
- sex
- M
- new_clusters
- C1
- umap1_2d
- 5.155334336
- umap2_2d
- 0.588353361
- umap1_3d
- 0.961024145
- umap2_3d
- -2.765686568
- umap3_3d
- 0.331616418
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- APICAL_SURFACE+0.350
- INTERFERON_GAMMA_RESPONSE+0.340
- PANCREAS_BETA_CELLS+0.280
- INFLAMMATORY_RESPONSE+0.270
- KRAS_SIGNALING_DN+0.230
- BILE_ACID_METABOLISM+0.210
- IL6_JAK_STAT3_SIGNALING+0.210
- XENOBIOTIC_METABOLISM+0.210
- KRAS_SIGNALING_UP+0.200
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.610
- MYC_TARGETS_V2-0.580
- MYC_TARGETS_V1-0.530
- MITOTIC_SPINDLE-0.470
- HEDGEHOG_SIGNALING-0.310
- DNA_REPAIR-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.240
- WNT_BETA_CATENIN_SIGNALING-0.210
- TGF_BETA_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2888 | Med | Medulloblastoma | 0.895 |
| 2 | MDT-AP-2047 | Med | Medulloblastoma | 0.882 |
| 3 | ERR2598283 | fetal | fetal | 0.872 |
| 4 | ERR2598329 | fetal | fetal | 0.861 |
| 5 | SRR657973 | GTEX | — | 0.857 |
| 6 | MDT-AP-2283 | Med | Medulloblastoma | 0.849 |
| 7 | MDT-AP-2579 | Med | Medulloblastoma | 0.836 |
| 8 | ERR2598268 | fetal | fetal | 0.834 |
| 9 | ERR2598267 | fetal | fetal | 0.831 |
| 10 | MDT-AP-0377 | Med | Medulloblastoma | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |